Recent guidelines for unstable angina and non-ST-segment-elevation myocardial infarction (NSTEMI) can be characterized as a progression and fine-tuning of past recommendations, which have contributed to a remarkable decline in the devastating outcomes. Dr. Elliott Antman, professor of medicine at Harvard Medical School and director of the Samuel A. Levine Cardiac Unit at Brigham and Women's Hospital in Boston, talks with host Dr. Janet Wright about the key updates to the latest guidelines and what we need to do to continue this trend toward fewer adverse outcomes. When initiating anticoagulant therapy, for instance, Dr. Antman says it is more important for your local institution to agree upon one therapeutic regimen, to avoid any unnecessary oscillations. Further, how do the guidelines address our oversight of patients' other medications, including nonsteroidal anti-inflammatory drugs and hormone replacement therapy? Tune in to find out more.
